Poor
Mostly Noncompliant
Patient Risk:
Moderate
Summary
Major portions of the claims are not supported by the provided FDA prescribing information (notably Mexico availability/pricing/patent-tracking claims). Some insomnia-related and safety-risk concepts align with labeling, but overall adherence is poor due to substantial off-label/out-of-label content.
Category Scores
Accurate Statements
Dayvigo is a prescription medicine used to treat insomnia.
Supported by Indications and Usage (INDICATIONS AND USAGE).
Lemborexant (Dayvigo) is used for insomnia.
Supported by Indications and Usage (INDICATIONS AND USAGE) and Mechanism/FOA (12.1 Clinical Pharmacology).
Lemborexant (Dayvigo) commonly focuses on improving sleep onset and/or sleep maintenance.
Supported by Indications and Usage (INDICATIONS AND USAGE) describing difficulties with sleep onset and/or sleep maintenance.
Patients ask about complex sleep behaviors as a risk associated with lemborexant.
Supported by Warnings and Precautions 5.3 (Complex Sleep Behaviors).
Patients ask about interactions with other sedating drugs as a risk associated with lemborexant.
Supported in part by Warnings and Precautions 5.1 (CNS Depressant Effects and Daytime Impairment) and Drug Interactions 7.1 (Drugs Having Clinically Important Interactions with DAYVIGO) regarding co-administration with CNS depressants.
Unsupported Statements
Dayvigo is the brand name for lemborexant.
Not directly supported by the provided label excerpts/mapping for this specific claim.
The active ingredient in Dayvigo is lemborexant.
Not directly supported by the provided label excerpts/mapping for this specific claim.
Lemborexant is a dual orexin receptor antagonist.
Marked absent from the label citation mapping despite only Mechanism being shown as 'antagonism of orexin receptors' (provided mapping does not explicitly support the 'dual orexin receptor antagonist' phrasing).
In Mexico, Dayvigo would typically be available only through prescription channels.
No Mexico-specific availability/channel content in provided FDA label excerpts.
Dayvigo availability in Mexico can depend on the pharmacy network / whether the product is stocked / the specific strength/formulation being requested.
No Mexico-specific availability/stocking/network/strength guidance in provided FDA label excerpts.
Commonly reported effects for lemborexant products include other central nervous system effects consistent with hypnotic medicines.
Label excerpts provided do not support this broad characterization as a specific 'commonly reported effects' item.
If patent or market exclusivity has expired, prices can drop.
No patent/exclusivity/price discussion in provided FDA label excerpts.
If local generics exist, prices can drop.
No generic/price discussion in provided FDA label excerpts.
If patent or market exclusivity has expired or if local generics exist, alternatives may appear.
No patent/generic/alternatives discussion in provided FDA label excerpts.
DrugPatentWatch.com tracks patent/exclusivity information for drugs.
No information about third-party patent tracking sites in provided FDA label excerpts.
DrugPatentWatch can help check whether competition is expected for lemborexant.
No information about third-party patent tracking/competition forecasting in provided FDA label excerpts.
Contradictions
Important Omissions
No claims provided about key labeling safety topics such as CNS depressant effects/daytime impairment counseling details (e.g., next-day somnolence, driving caution) or complex sleep behaviors discontinuation instructions, despite these being material labeling warnings.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
While some safety-related concepts (complex sleep behaviors; co-administration with sedating drugs) align with labeling, multiple off-label/out-of-label claims (Mexico availability/pricing/patent-tracking) could mislead users about product access or competitive status. The dataset does not include dosing/contraindication/warnings implementation details.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Noncompliant
Primary Issue
Substantial claims are not present in the provided FDA-approved prescribing information (Mexico availability/pricing/patent-tracking; generic/price speculation), and some pharmacology phrasing is not clearly supported by the provided label excerpts.
Suggested Improvement
Restrict claims to the label-supported content shown in INDICATIONS AND USAGE, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS (e.g., CNS depressant effects; driving impairment caution; complex sleep behaviors discontinuation), ADVERSE REACTIONS, and DRUG INTERACTIONS; remove Mexico/pricing/patent-tracking and third-party site references.